The FDA accepted for priority review a supplemental biologics license request (sBLA) for intravenous (IV) efgartigimod alfa-fcab (Vyvgart; argenx) for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). With this announcement, the treatment was granted a Prescription Drug user Fee Act target action date of May 10, 2026.1
FDA Accepts Priority Review of Vyvgart for Seronegative myasthenia Gravis
The Food and Drug Management (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Vyvgart (efgartigimod alfa-fcab),developed by argenx,offering new hope for individuals battling acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). A decision is anticipated by May 10, 2026.1 This marks a significant step toward perhaps expanding treatment options for a challenging-to-treat subset of myasthenia gravis patients.
Understanding Myasthenia gravis and the Role of Vyvgart
Generalized myasthenia gravis (gMG) is a chronic autoimmune neuromuscular disease that leads to fluctuating muscle weakness and fatigue. The condition arises when antibodies disrupt communication between nerves and muscles. Approximately 80% of individuals with gMG test positive for antibodies against the acetylcholine receptor (AChR-Ab), classified as achr-Ab seropositive. Though, around 20% test negative for these antibodies, falling into the AChR-Ab seronegative category.1 These patients often present diagnostic and therapeutic challenges.
Vyvgart represents a first-in-class neonatal Fc receptor antagonist. These receptors play a role in protecting IgG antibodies from degradation, effectively increasing antibody levels. By blocking these receptors, Vyvgart reduces the circulating levels of harmful autoantibodies that attack the neuromuscular junction. Initially approved in December 2021 for AChR-Ab seropositive gMG2, Vyvgart’s potential extension to include AChR-Ab seronegative gMG addresses a critical unmet medical need.
The ADAPT SERON Trial: Demonstrating Efficacy in a Challenging Population
The FDA’s decision to grant priority review is based on compelling data from the phase 3 ADAPT SERON clinical trial (NCT06298552)3. This randomized, double-blind, placebo-controlled study, conducted across multiple centers in North America, europe, China, and the Middle East, specifically investigated the effects of IV efgartigimod in adult patients with AChR-Ab seronegative gMG. the trial evaluated patients across all three subtypes of the condition: muscle-specific tyrosine kinase-positive (MuSK+), low-density lipoprotein receptor-related protein-positive (LRP4+), and triple seronegative gMG.
A total of 119 patients participated in the trial, which was divided into two phases. Phase A involved a randomized allocation of participants to receive either four weekly infusions of IV efgartigimod or a placebo, followed by a five-week follow-up period for primary analysis. Phase B comprised an open-label extension, where patients received two cycles of four weekly infusions, with subsequent cycles adjusted based on their clinical response.3,4 Importantly,all participants were already receiving stable doses of standard gMG treatments,including acetylcholinesterase inhibitors,corticosteroids,or immunosuppressants.
The primary endpoint of the trial—change in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score from baseline to day 29—demonstrated a statistically significant betterment in patients receiving IV efgartigimod (P = .0068).Specifically, the treatment group experienced a clinically meaningful 3.35-point improvement in MG-ADL scores compared to placebo.1 Further analysis revealed consistent improvements in MG-ADL and Quantitative Myasthenia Gravis (QMG) scores across treatment cycles and within all patient subgroups,including those with MuSK+,LRP4+,and triple seronegative gMG.
The safety profile of IV efgartigimod in this trial was consistent with previous findings, with no new safety concerns identified by argenx.1 This reinforces its generally well-tolerated nature among gMG patients.
What This Means for Patients
The potential approval of Vyvgart for AChR-Ab seronegative gMG represents a major step forward in treatment options. Patients who don’t respond well to current therapies, or struggle with side effects, may benefit from an additional therapeutic avenue. “Patients living with seronegative gMG continue to face limited treatment options, and there remains a significant need to meaningfully improve their lives,” said Luc Truyen, MD, PhD, chief medical officer of argenx. “The FDA’s acceptance of our sBLA with Priority Review status reflects the potential of [IV efgartigimod] to address this need.”1
Potential Risks and Considerations
As with any medication, Vyvgart carries potential risks. The manufacturer advises against its use in patients with a known serious allergy to efgartigimod alfa or any of its components. Serious allergic reactions and temporary decreases in blood pressure,potentially leading to fainting,are also possible side effects.1 A thorough discussion with a healthcare professional is essential to evaluate individual risks and benefits.
